Summitry LLC’s Biogen BIIB Stock Holding History

Summitry LLC’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$894K	Sell	4,137 -600	-13%	-$115K	0.03%	106
2026 Q1	$868K	Sell	4,737 -57	-1%	-$10.5K	0.03%	91
2025 Q4	$844K	Sell	4,794 -1,249	-21%	-$204K	0.04%	79
2025 Q3	$847K	Buy	6,043 +3,392	+128%	+$459K	0.04%	69
2025 Q2	$333K	Buy	+2,651	New	+$330K	0.02%	124

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Summitry LLC's BIIB Position: Q2 2026 in Review

Summitry LLC reduced its Biogen (BIIB) stake by 13% in Q2 2026, selling an estimated $115K and leaving 4,137 shares worth $894K. The position accounts for 0.03% of the portfolio, ranked #106.

Summitry LLC first reported a position in BIIB in Q2 2025 and has held it in 5 quarters since. 1,041 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Summitry LLC held 4,137 shares of Biogen worth $894K as of Q2 2026.
Summitry LLC sold 600 Biogen shares in Q2 2026, an estimated $115K.
Biogen made up 0.03% of Summitry LLC's portfolio in Q2 2026, its #106 holding.
Summitry LLC first reported a position in Biogen in Q2 2025 and has held it in 5 quarters since.
1,041 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Summitry LLC's 13F filing for Q2 2026, filed 21 Jul 2026.